These various subtypes pose unique challenges in breast cancer treatment, especially in the case of triple-negative breast cancer (TNBC), which lacks hormone receptors and operates in a challenging, “cold” environment where traditional therapies struggle to be effective. This evidence concerns the gene NR4A1 and breast cancer.